Siraitia grosvenorii Residual Extract Inhibits Inflammation in RAW264.7 Macrophages and Attenuates Osteoarthritis Progression in a Rat Model
Open Access
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterised by cartilage degeneration and chondrocyte inflammation. We investigated the anti-inflammatory effects of the Siraitia grosvenorii residual extract (SGRE) in lipopolysaccharide (LPS)-induced RAW264.7 macrophages in vitro and its anti-osteoarthritic effects in a monosodium iodoacetate (MIA)-induced OA rat model. SGRE dose-dependently decreased nitric oxide (NO) production in LPS-induced RAW264.7 cells. Moreover, SGRE reduced the pro-inflammatory mediator (cyclooxygenase-2 (COX2), inducible NO synthase (iNOS), and prostaglandin E2 (PGE2)) and pro-inflammatory cytokine (interleukin-(IL)-1β, IL-6, and tumour necrosis factor (TNF-α)) levels. SGRE suppressed nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathway activation in RAW264.7 macrophages, thus reducing inflammation. Rats were orally administered SGRE (150 or 200 mg/kg) or the positive control drug JOINS (20 mg/kg) 3 days before MIA injection, and once daily for 21 days thereafter. SGRE elevated the hind paw weight-bearing distribution, thus relieving pain. It also reduced inflammation by inhibiting inflammatory mediator (iNOS, COX-2, 5-LOX, PGE2, and LTB4) and cytokine (IL-1β, IL-6, and TNF-α) expression, downregulating cartilage-degrading enzymes, such as MMP-1, -2, -9, and -13. SGRE significantly reduced the SOX9 and extracellular matrix component (ACAN and COL2A1) levels. Therefore, SGRE is a potential therapeutic active agent against inflammation and OA.Keywords
Funding Information
- Korea Institute of Oriental Medicine (KSN2022310, 2022-DD-RD-0465)
- INNOPOLIS foundation of Korea (KSN2022310, 2022-DD-RD-0465)
This publication has 46 references indexed in Scilit:
- Inflammatory mediators in osteoarthritis: A critical review of the state-of-the-art, current prospects, and future challengesBone, 2016
- The Role of Innate Immunity in Osteoarthritis: When Our First Line of Defense Goes On the OffensiveThe Journal of Rheumatology, 2015
- The Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of OsteoarthritisMediators of Inflammation, 2014
- Biologic agents in osteoarthritis: hopes and disappointmentsNature Reviews Rheumatology, 2013
- New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progressionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012
- Proteases involved in cartilage matrix degradation in osteoarthritisBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2012
- Role of proinflammatory cytokines in the pathophysiology of osteoarthritisNature Reviews Rheumatology, 2010
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- MAPK signalling pathways as molecular targets for anti-inflammatory therapy—from molecular mechanisms to therapeutic benefitsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2005
- The two NF-κB activation pathways and their role in innate and adaptive immunityTrends in Immunology, 2004